PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2014.0512014474616-629Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II TrialDae Ho Lee, Jung Shin Lee, Jie Wang, Te-Chun Hsia, Xin Wang, Jongseok Kim, Mauro Orlandohttp://e-crt.org/upload/pdf/crt-2014-051.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2014.051, http://www.e-crt.org/upload/pdf/crt-2014-051.pdf
Annals of Oncology10.1093/annonc/mds409201223ix400A Randomized Phase 2 Study of Erlotinib Plus Pemetrexed vs Erlotinib or Pemetrexed Alone as Second-Line Treatment for Never-Smoker Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer (NSCLC)D.H. Lee, J.S. Lee, S.W. Kim, J. Rodrigues Pereira, B. Han, X.Q. Song, J. Wang, H.-K. Kim, T.P. Sahoo, R. Digumarti, X. Wang, S. Altug, M. Orlandohttps://api.elsevier.com/content/article/PII:S0923753420337856?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420337856?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/23/suppl_9/ix400/6677253/mds409.pdf
European Journal of Cancer10.1016/j.ejca.2013.06.035201349153111-3121Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancerDae Ho Lee, Jung Shin Lee, Sang-We Kim, José Rodrigues-Pereira, Baohui Han, Xiang-Qun Song, Jie Wang, Hoon-Kyo Kim, Tarini Prasad Sahoo, Raghunadharao Digumarti, Xin Wang, Sedat Altug, Mauro Orlandohttps://api.elsevier.com/content/article/PII:S0959804913005303?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804913005303?httpAccept=text/plain
European Journal of Cancer10.1016/j.ejca.2014.03.00720145091571-1580A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancerChristian Dittrich, Zsolt Papai-Szekely, Nuria Vinolas, Christer Sederholm, Joerg T. Hartmann, Dirk Behringer, Gbenga Kazeem, Durisala Desaiah, Monika I. Leschinger, Joachim von Pawelhttps://api.elsevier.com/content/article/PII:S0959804914002500?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804914002500?httpAccept=text/plain
Lung Cancer: Targets and Therapy10.2147/lctt.s33608201243Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysisVassilis Fragoulakis, Athanasios Pallis, Kateilidou, Maniadakis, Georgouliashttps://www.dovepress.com/getfile.php?fileID=13298
Lung Cancer10.1016/j.lungcan.2012.03.0112012772346-352Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancerMyung-Ju Ahn, James Chih-Hsin Yang, Jun Liang, Jin-Hyoung Kang, Qingyu Xiu, Yuh-Min Chen, Julie Michelle Blair, Guangbin Peng, Carlos Linn, Mauro Orlandohttps://api.elsevier.com/content/article/PII:S0169500212001225?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500212001225?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2015.12.0042016172150-160First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III TrialMark Boye, Xin Wang, Vichien Srimuninnimit, Jin Hyoung Kang, Chun-Ming Tsai, Mauro Orlando, Tarun Puri, Jong Seok Kim, Narayan Rajan, James Chih-Hsin Yanghttps://api.elsevier.com/content/article/PII:S1525730415002983?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730415002983?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2016.10.003201718160-67Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung CancerTianhong Li, Bilal Piperdi, William V. Walsh, Mimi Kim, Laurel A. Beckett, Rasim Gucalp, Missak Haigentz, Venu G. Bathini, Huiyu Wen, Kaili Zhou, Patricia B. Pasquinelli, Srikanth Gajavelli, Meera Sreedhara, Xianhong Xie, Primo N. Lara, David R. Gandara, Roman Perez-Solerhttps://api.elsevier.com/content/article/PII:S1525730416303461?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S1525730416303461?httpAccept=text/xml
Journal of Thoracic Oncology10.1097/jto.0b013e3181d1273d201055688-695Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III TrialChih-Hsin Yang, Lorinda Simms, Keunchil Park, Jin Soo Lee, Giorgio Scagliotti, Mauro Orlandohttps://api.elsevier.com/content/article/PII:S1556086415321432?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1556086415321432?httpAccept=text/plain
Value in Health10.1016/s1098-3015(11)71939-82010137A259PCN43 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN ITALYS Ravera, S Walzer, J Rayhttps://api.elsevier.com/content/article/PII:S1098301511719398?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301511719398?httpAccept=text/plain